Chimerna Therapeutics Inc, based in New York, NY, is a pioneering biotech company that has developed a groundbreaking platform technology for RNA therapeutics. Their Tornado technology overcomes the limitations of RNA stability and abundance, enabling robust endogenous expression of RNAs and RNA aptamers. With a wide range of applications including molecular sensors, protein expression, and aptamers, Chimerna is at the forefront of advancing the field of RNA-based therapies.
Led by a team of experienced scientists and researchers, including CEO Brian Pickering and CSO Jacob Litke, Chimerna Therapeutics is dedicated to revolutionizing the way RNA therapeutics are developed and utilized. Their innovative approach has garnered recognition and support, with scientific advisor Dr. Samie Jaffrey contributing to the company's success through his groundbreaking work in RNA biology and gene regulation. With exciting developments in their pipeline, Chimerna Therapeutics is poised to make a significant impact in the field of RNA therapeutics.
Generated from the website